Trisomy 4 is not comparable to common autosomal trisomies (21, 18, 13). Chromosome 4 carries a much larger volume of genetic material than chromosome 21, making the presence of a complete extra copy generally incompatible with life. Documented viable cases in the literature correspond almost exclusively to mosaic forms or partial trisomies, where only a portion of the short arm or long arm of chromosome 4 is duplicated.
Complete, mosaic, or partial trisomy 4: cytogenetic distinction
The frequent confusion between these three entities skews the interpretation of prognosis. A homogeneous trisomy 4 (present in all cells) leads in the vast majority of cases to early spontaneous abortion, often in the first trimester. Chromosomal abnormalities account for about half of early miscarriages, and trisomies of large chromosomes contribute significantly.
In mosaic trisomy 4, only a fraction of the body’s cells carry the extra chromosome. The phenotype directly depends on the proportion of trisomic cells and their tissue distribution. We observe considerable clinical variability: two patients with the same cytogenetic rearrangement can present very different clinical pictures.
Partial trisomy 4 involves a duplicated chromosomal segment, often resulting from a balanced parental translocation. The phenotype varies according to the duplicated region (short arm 4p or long arm 4q) and the size of the fragment. To delve deeper into the characteristics of trisomy 4, distinguishing between these mechanisms remains the first diagnostic reflex to adopt.
Congenital malformations and organ involvement in trisomy 4
The clinical picture associated with viable forms of trisomy 4 combines craniofacial anomalies, growth retardation, and visceral malformations. Reported craniofacial anomalies include variable facial dysmorphism, sometimes associated with cleft lip and palate or ocular anomalies.
The prognosis depends more on cardiac, renal, and neurological involvement than on the chromosomal label itself. Among the documented conditions:
- Congenital heart defects (ventricular septal defects, tetralogy of Fallot, or other conotruncal heart diseases), which often constitute the limiting factor for neonatal survival.
- Renal anomalies (unilateral renal agenesis, vesicoureteral reflux, urinary tract malformations), detectable by prenatal ultrasound but varying in severity.
- Neurological developmental delay, ranging from moderate psychomotor delay to more marked intellectual disability depending on the extent of genomic imbalance.
Both prenatal and postnatal growth retardation is almost constant in documented forms. Children frequently present with a birth weight below normal, with slowed growth in stature during the early years.
Prenatal diagnosis of trisomy 4: karyotype, FISH, and CGH-array
Standard prenatal screening (maternal serum markers, circulating free fetal DNA) is calibrated for trisomies 21, 18, and 13. Trisomy 4 is not targeted by routine screening tests, which explains why it is often discovered during a fetal karyotype prescribed for another indication (ultrasound malformation, growth retardation, increased nuchal translucency).
Karyotyping on chorionic villi or amniotic fluid remains the reference technique for identifying a complete or mosaic trisomy. The FISH technique (fluorescence in situ hybridization) allows for rapid confirmation of a number anomaly on chromosome 4.
The CGH-array (comparative genomic hybridization on a chip) provides superior resolution for partial trisomies. It precisely delineates the duplicated segment and allows for a finer genotype-phenotype correlation. We recommend this analysis in all cases of suspected partial trisomy 4, as the size of the duplicated segment radically alters the prognosis.
Placenta-confined anomaly
A recognized diagnostic pitfall concerns placental mosaicism. Chorionic villus sampling may reveal a trisomy 4 that does not exist in fetal cells. This situation leads to follow-up amniocenteses to verify the actual fetal karyotype. However, the presence of a chromosomal anomaly confined to the placenta can disrupt placental function and lead to intrauterine growth retardation.
Management and follow-up of viable forms of trisomy 4
There is no curative treatment for a constitutional chromosomal anomaly. Management relies on treating associated malformations and a multidisciplinary follow-up tailored to the clinical picture of each patient.
Neonatal cardiac surgery is the priority when a complex heart defect is identified. Nephrological follow-up is essential in the case of renal anomalies. Psychomotor and speech therapy rehabilitation begins in the first months of life for children with developmental delays.
Genetic counseling plays a central role. When a balanced parental translocation is identified as the origin of partial trisomy 4, the recurrence risk for subsequent pregnancies can be quantified. Karyotyping of both parents is systematically offered.
- Regular cardiological follow-up with control echocardiograms, even in the absence of initial symptoms.
- Repeated renal and ultrasound assessments during early childhood to detect late-expressing anomalies.
- Standardized neurodevelopmental evaluation at regular intervals to adapt rehabilitation interventions.
- Psychological support for families, often facing a rare pathology without a structured patient community.
The rarity of trisomy 4 limits the available longitudinal data. Each published case enriches the genotype-phenotype correlation and refines the information provided to families during genetic counseling. Registries of congenital anomalies, such as those coordinated by Santé publique France, contribute to documenting these exceptional situations, even if specific data on chromosome 4 remain fragmented.